TREATMENT OF EPITHELIAL OVARIAN TUMORS: CYTOREDUCTIVE SURGERY PROTOCOLS AND ADJUVANT CHEMOTHERAPY
DOI:
https://doi.org/10.56238/arev8n3-011Keywords:
Epithelial Ovarian Tumors, Cytoreduction, Adjuvant Chemotherapy, Gut Microbiome, Cannabinoid ReceptorsAbstract
Epithelial ovarian cancer (EOC) is the most lethal malignant neoplasm of the female reproductive tract, frequently diagnosed at advanced stages. Standard treatment combines maximal surgical cytoreduction and adjuvant platinum-based chemotherapy. This study, a narrative literature review, examines the biological complexity and therapeutic challenges of EOC. Treatment efficacy is modulated by factors such as tumor metabolic reprogramming, mitochondrial dysfunction, and, notably, the integrity of the gut microbiota, which can confer cisplatin resistance. Differential expression of biomarkers, such as the cannabinoid receptor CB1R, aids in pathological classification. In pregnant women, management requires protocols that balance maternal-fetal safety. It is concluded that success in addressing EOC depends on the transition from static protocols to personalized and multidisciplinary approaches that consider the patient's complete biology, including the tumor microenvironment and molecular factors, to reduce high recurrence rates.
Downloads
References
CHAMBERS, L. M. et al. Disruption of the gut microbiota confers cisplatin resistance in epithelial ovarian cancer. Cancer Research, v. 82, n. 24, p. 4654-4669, 2022. DOI: https://doi.org/10.1158/0008-5472.CAN-22-0455
CHAROENKWAN, K. et al. Alterations in mitochondria isolated from peripheral blood mononuclear cells and tumors of patients with epithelial ovarian cancers. Scientific Reports, v. 14, n. 1, p. 15, 2024. DOI: https://doi.org/10.1038/s41598-023-51009-z
CHEN, C. et al. Machine learning-derived diagnostic model of epithelial ovarian cancer based on gut microbiome signatures. Journal of Translational Medicine, v. 23, n. 319, 2025. DOI: https://doi.org/10.1186/s12967-025-06339-z
CHUNG, D. C. et al. Characterization of innate lymphoid cell subsets infiltrating melanoma and epithelial ovarian tumors. Oncoimmunology, v. 13, n. 1, p. 2349347, 2024. DOI: https://doi.org/10.1080/2162402X.2024.2349347
FRUSCIO, R. et al. Epithelial ovarian cancer and borderline tumors during pregnancy: a report from the International Network on Cancer, Infertility, and Pregnancy. International Journal of Gynecological Cancer, v. 35, n. 2, 2025. DOI: https://doi.org/10.1016/j.ijgc.2024.100053
RONCHI, A. et al. Endocannabinoid system expression in ovarian epithelial tumors according to the dualistic model of ovarian carcinogenesis. European Review for Medical and Pharmacological Sciences, v. 25, p. 4678-4686, 2021.
WANG, M. et al. Tumor metabolism rewiring in epithelial ovarian cancer. Journal of Ovarian Research, v. 16, n. 108, 2023. DOI: https://doi.org/10.1186/s13048-023-01196-0
